NA Vaccine Institute (CEO Kim Dong-ho), a company that develops vaccines to prevent and treat infectious diseases and incurable cancers, published a paper confirming the mechanism and effects of an innovative anti-cancer treatment based on Nexavant, an immune booster developed in-house, in the academic journal Cancers. It was announced on the 11th that it was published in '.

Nexavant is an immune-enhancing substance developed by the NA Vaccine Institute and was developed as an anti-cancer treatment substance. Through this study, it was confirmed that Nexavant has superior anticancer effects in various cancer types through a new mechanism. In other words, when Nexavant is administered to a tumor, it has been confirmed that it has the ability to convert a 'hot tumor' that is easy to treat by inducing immune cells in a 'cold tumor' that is difficult to treat due to a lack of immune cells. . In particular, when used in combination with the ‘PD1’ antibody, which is popular for cancer treatment, it showed a strong synergy effect in skin cancer and triple-negative breast cancer, which are representative cold tumors.

Additionally, when used in combination with currently commercially available PD1 antibodies using humanized mice, it produces the same synergistic effect in skin cancer and triple-negative breast cancer. Uniquely, specific PD1 antibodies such as ‘Obdivo’ showed a complete remission of more than 80% in triple-negative breast cancer.

In addition, Nexavant shows a remarkable effect of suppressing lung metastasis and improving survival rate by more than 40% when inhaled into the lungs. Nexavant was produced under good manufacturing and quality management practices (GMP) and is being developed as a variety of vaccine adjuvants and a central cancer treatment substance. An official from the NA Vaccine Institute said, “Based on the academic community’s objective recognition of this paper, we plan to develop lung cancer treatments and shared treatments with specific PD1 companies.”